Literature DB >> 31195109

Models with interactions overestimated heterogeneity of treatment effects and were prone to treatment mistargeting.

David van Klaveren1, Theodor A Balan2, Ewout W Steyerberg3, David M Kent4.   

Abstract

OBJECTIVES: We aimed to compare the performance of different regression modeling approaches for the prediction of heterogeneous treatment effects. STUDY DESIGN AND
SETTING: We simulated trial samples (n = 3,600; 80% power for a treatment odds ratio of 0.8) from a superpopulation (N = 1,000,000) with 12 binary risk predictors, both without and with six true treatment interactions. We assessed predictions of treatment benefit for four regression models: a "risk model" (with a constant effect of treatment assignment) and three "effect models" (including interactions of risk predictors with treatment assignment). Three novel performance measures were evaluated: calibration for benefit (i.e., observed vs. predicted risk difference in treated vs. untreated), discrimination for benefit, and prediction error for benefit.
RESULTS: The risk modeling approach was well-calibrated for benefit, whereas effect models were consistently overfit, even with doubled sample sizes. Penalized regression reduced miscalibration of the effect models considerably. In terms of discrimination and prediction error, the risk modeling approach was superior in the absence of true treatment effect interactions, whereas penalized regression was optimal in the presence of true treatment interactions.
CONCLUSION: A risk modeling approach yields models consistently well calibrated for benefit. Effect modeling may improve discrimination for benefit in the presence of true interactions but is prone to overfitting. Hence, effect models-including only plausible interactions-should be fitted using penalized regression.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Heterogeneity of treatment effect; Penalized regression analysis; Personalized medicine; Prediction models; Regression analysis; Treatment benefit

Mesh:

Year:  2019        PMID: 31195109      PMCID: PMC7497896          DOI: 10.1016/j.jclinepi.2019.05.029

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  20 in total

1.  Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical Trials.

Authors:  Joshua D Wallach; Patrick G Sullivan; John F Trepanowski; Kristin L Sainani; Ewout W Steyerberg; John P A Ioannidis
Journal:  JAMA Intern Med       Date:  2017-04-01       Impact factor: 21.873

2.  Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification.

Authors:  David M Kent; Rodney A Hayward
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272

Review 3.  A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research.

Authors:  Ravi Varadhan; Jodi B Segal; Cynthia M Boyd; Albert W Wu; Carlos O Weiss
Journal:  J Clin Epidemiol       Date:  2013-05-04       Impact factor: 6.437

4.  Subgroup identification based on differential effect search--a recursive partitioning method for establishing response to treatment in patient subpopulations.

Authors:  Ilya Lipkovich; Alex Dmitrienko; Jonathan Denne; Gregory Enas
Journal:  Stat Med       Date:  2011-07-22       Impact factor: 2.373

5.  Estimates of absolute treatment benefit for individual patients required careful modeling of statistical interactions.

Authors:  David van Klaveren; Yvonne Vergouwe; Vasim Farooq; Patrick W Serruys; Ewout W Steyerberg
Journal:  J Clin Epidemiol       Date:  2015-02-27       Impact factor: 6.437

6.  The proposed 'concordance-statistic for benefit' provided a useful metric when modeling heterogeneous treatment effects.

Authors:  David van Klaveren; Ewout W Steyerberg; Patrick W Serruys; David M Kent
Journal:  J Clin Epidemiol       Date:  2017-11-11       Impact factor: 6.437

7.  Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials.

Authors:  James F Burke; Rodney A Hayward; Jason P Nelson; David M Kent
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-01-14

8.  Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal.

Authors:  David M Kent; Peter M Rothwell; John P A Ioannidis; Doug G Altman; Rodney A Hayward
Journal:  Trials       Date:  2010-08-12       Impact factor: 2.279

9.  Events per variable (EPV) and the relative performance of different strategies for estimating the out-of-sample validity of logistic regression models.

Authors:  Peter C Austin; Ewout W Steyerberg
Journal:  Stat Methods Med Res       Date:  2014-11-19       Impact factor: 3.021

10.  Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.

Authors:  Sanjay Basu; Jeremy B Sussman; Joseph Rigdon; Lauren Steimle; Brian T Denton; Rodney A Hayward
Journal:  PLoS Med       Date:  2017-10-17       Impact factor: 11.069

View more
  13 in total

1.  Development of a model to predict psychotherapy response for depression among Veterans.

Authors:  Hannah N Ziobrowski; Ruifeng Cui; Eric L Ross; Howard Liu; Victor Puac-Polanco; Brett Turner; Lucinda B Leung; Robert M Bossarte; Corey Bryant; Wilfred R Pigeon; David W Oslin; Edward P Post; Alan M Zaslavsky; Jose R Zubizarreta; Andrew A Nierenberg; Alex Luedtke; Chris J Kennedy; Ronald C Kessler
Journal:  Psychol Med       Date:  2022-02-11       Impact factor: 10.592

2.  Authors' Reply: Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange.

Authors:  Dorian Nezam; Raphaël Porcher; François Grolleau; Benjamin Terrier
Journal:  J Am Soc Nephrol       Date:  2022-04-11       Impact factor: 14.978

3.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.

Authors:  David M Kent; David van Klaveren; Jessica K Paulus; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

4.  Individual participant data meta-analysis to examine interactions between treatment effect and participant-level covariates: Statistical recommendations for conduct and planning.

Authors:  Richard D Riley; Thomas P A Debray; David Fisher; Miriam Hattle; Nadine Marlin; Jeroen Hoogland; Francois Gueyffier; Jan A Staessen; Jiguang Wang; Karel G M Moons; Johannes B Reitsma; Joie Ensor
Journal:  Stat Med       Date:  2020-04-30       Impact factor: 2.373

5.  Testing for a Sweet Spot in Randomized Trials.

Authors:  Donald A Redelmeier; Deva Thiruchelvam; Robert J Tibshirani
Journal:  Med Decis Making       Date:  2021-08-11       Impact factor: 2.583

6.  Detecting Heterogeneity of Intervention Effects Using Analysis and Meta-analysis of Differences in Variance Between Trial Arms.

Authors:  Harriet L Mills; Julian P T Higgins; Richard W Morris; David Kessler; Jon Heron; Nicola Wiles; George Davey Smith; Kate Tilling
Journal:  Epidemiology       Date:  2021-11-01       Impact factor: 4.822

7.  A two-stage prediction model for heterogeneous effects of treatments.

Authors:  Konstantina Chalkou; Ewout Steyerberg; Matthias Egger; Andrea Manca; Fabio Pellegrini; Georgia Salanti
Journal:  Stat Med       Date:  2021-05-27       Impact factor: 2.497

8.  Time to reality check the promises of machine learning-powered precision medicine.

Authors:  Jack Wilkinson; Kellyn F Arnold; Eleanor J Murray; Maarten van Smeden; Kareem Carr; Rachel Sippy; Marc de Kamps; Andrew Beam; Stefan Konigorski; Christoph Lippert; Mark S Gilthorpe; Peter W G Tennant
Journal:  Lancet Digit Health       Date:  2020-09-16

Review 9.  Predictive approaches to heterogeneous treatment effects: a scoping review.

Authors:  Alexandros Rekkas; Jessica K Paulus; Gowri Raman; John B Wong; Ewout W Steyerberg; Peter R Rijnbeek; David M Kent; David van Klaveren
Journal:  BMC Med Res Methodol       Date:  2020-10-23       Impact factor: 4.615

10.  Identifying trauma patients with benefit from direct transportation to Level-1 trauma centers.

Authors:  Charlie A Sewalt; Benjamin Y Gravesteijn; Daan Nieboer; Ewout W Steyerberg; Dennis Den Hartog; David Van Klaveren
Journal:  BMC Emerg Med       Date:  2021-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.